Mineralys Therapeutics Financials - Benzinga

Mineralys Therapeutics Inc

MLYSNASDAQ

Trade with Public

Trade with Public

$25.86

-0.73-2.75%

近くで: Sep 25, 5:00 PM EST

$25.86

N/A

時間外: 4:00 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Mineralys Therapeutics Financials

Mineralys Therapeutics (MLYS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Mineralys Therapeutics Q2 EPS $(2.85) Misses $(0.55) Estimate

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Mineralys Therapeutics Q1 EPS $(0.47), Inline

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This is a 40.51 percent increase over losses of $(0.79) per share from the same period last

Benzinga Newsdesk

PRO
Mineralys Therapeutics Q4 EPS $(0.40) Beats $(0.58) Estimate

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.58) by 30.68 percent. This is a 59.18 percent increase over losses of $(0.98) per share

Benzinga Newsdesk

Earnings Scheduled For March 12, 2026

Benzinga Insights

PRO
Mineralys Therapeutics Q3 EPS $(0.52) Beats $(0.65) Estimate

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.65) by 19.38 percent. This is a 53.98 percent increase over losses of $(1.13) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved